ClinicalTrials.gg
Sign In

Amyloid Neuropathies, Familial clinical trials

The registry lists 188 studies for Amyloid Neuropathies, Familial across more than 10 countries. 94 are recruiting or about to start. 115 of them are mainly about Amyloid Neuropathies, Familial (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Amyloidosis, Hereditary, Transthyretin-Related too: 241 studies, 112 open.

Get an email when these change. Save the Amyloid Neuropathies, Familial studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Recruiting
69
Completed
57
Not yet recruiting
17
Status unknown
15
Active, not recruiting
9
Enrolling by invitation
8

Phase

Phase 3
23
Phase 2
13
Phase 1
10
Phase 4
9
Early Phase 1
4

Where

United States
58
France
35
Germany
28
Italy
27
United Kingdom
24
Spain
20

Who runs them

Eidos Therapeutics, a BridgeBio company (9) · Pfizer (9) · Alnylam Pharmaceuticals (9) · Brigham and Women's Hospital (6) · University Hospital Center of Martinique (5) · University Hospital, Essen (5) · Steen Hvitfeldt Poulsen (4) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (3)

What is being tested here

Drugs under test in Amyloid Neuropathies, Familial studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Acoramidis369
Enavogliflozin101
Dobutamine101
Genistein101
Tafamidis045
Florbetaben f-18014
Patisiran023
NTLA-2001012
Inotersen022
Revusiran012

Coming up

6phase 3 studies under way
27studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stop at 75 or younger. 7 (10%) take children under 18. 1 (1%) are for women only and 1 (1%) for men only; 9 (13%) take healthy volunteers.

Recruiting studies that take each age, of 69
AgeWomenMen
106 (9%)5 (7%)
1849 (71%)48 (70%)
3053 (77%)52 (75%)
4056 (81%)55 (80%)
5060 (87%)59 (86%)
6567 (97%)67 (97%)
7567 (97%)67 (97%)
8561 (88%)61 (88%)

Across all 188 studies, recruiting or not: 4% stop at 75 or younger and 1% at 65; 9% take children; 1% are for women only and 1% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Amyloid Neuropathies, Familial studies take

Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase35 mo18–67 · 30 studies——
Observational65 mo30–110 · 74 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 188. Browse all 188 → or search them.